12 Jan 2022 – ground-breaking 400 patient 'BIOPATTERN' trial using the PlaqueTec LBS™ catheter in collaboration with Royal Papworth Hospital, Cambridge, to start Q2 2022. This unique clinical study will open a new frontier in the understanding of Coronary Artery Disease and pave the way for the development of new, disease-specific personalised treatments.
PlaqueTec is paving the way to personalised medicine for Coronary Artery Disease (CAD).
We envision a future in which clinicians can accurately assess patients’ risk of future events and apply individualised treatment. Our Liquid Biopsy System™ (LBS™) is a revolutionary technology that facilitates the identification and collection of biomarker samples from vulnerable plaque within coronary arteries, providing clinically valuable information pertaining to vascular function, inflammation, and coronary plaque progression.
Guided by world leaders in cardiovascular medicine, PlaqueTec is mapping the biological processes of CAD in more detail than has ever been possible. We are building a database of identified biomarkers to be used by CAD clinicians, researchers, and biopharmaceutical companies to conduct translational research and develop next-generation personalised therapies.
Our aim is to provide better benchmarks for new and existing drug performance, and to facilitate the development of new drugs that target the inflammatory processes underlying CAD progression.
PlaqueTec is pioneering the development of biomarker-based strategies to transform the prevention, diagnosis, and treatment of Coronary Artery Disease, the leading cause of death worldwide.
Watch the PlaqueTec Liquid Biopsy System™ in action.